An antigenomic strategy for treating heteroplasmic mtDNA disorders.

TitleAn antigenomic strategy for treating heteroplasmic mtDNA disorders.
Publication TypeJournal Article
Year of Publication2001
AuthorsTaylor, RW, Wardell, TM, Smith, PM, Muratovska, A, Murphy, MP, Turnbull, DM, Lightowlers, RN
JournalAdv Drug Deliv Rev
Volume49
Issue1-2
Pagination121-5
Date Published2001 Jul 02
ISSN0169-409X
KeywordsDNA Replication, DNA, Mitochondrial, Gene Targeting, Humans, Mitochondrial Myopathies, Peptide Nucleic Acids
Abstract

In mammals, mitochondrial DNA (mtDNA) is the only autonomously replicating source of DNA outside the nucleus. Housed in the mitochondrial matrix, this molecule encodes thirteen polypeptides, all of which are believed to be essential components of the mitochondrial respiratory chain. Defects of the mitochondrial genome can cause severe neurological and multi-systemic disorders. As the genetic defect causes a dysfunction in the terminal stage of oxidative metabolism, there is little potential for pharmacological intervention. Thus, there is currently no effective therapy for these chronic progressive disorders. In the disease state, pathogenic mtDNA molecules often cohabit the same cell and tissue with wild type mtDNA, a situation termed heteroplasmy. Manifestation of biochemical and clinical defects occur only when a threshold level of heteroplasmy has been passed. The mitochondrial genome must be continually turned over. Consequently, if a pathogenic mtDNA molecule were to be targeted to prevent it from replicating, the wild type copy would be given a propagative advantage. Over time, therefore, the biochemical and, potentially, the clinical deficiency could be reversed. This manuscript summarises our attempts to identify such an antigenomic molecule, to localise this molecule to mitochondria and to assess its function in whole cells. Finally, we discuss the importance of identifying and designing new antigenomic molecules which may prove effective in treating patients with disorders of the mitochondrial genome.

DOI10.1016/s0169-409x(01)00130-2
Alternate JournalAdv. Drug Deliv. Rev.
Citation Key10.1016/s0169-409x(01)00130-2
PubMed ID11377807